{"id":"NCT01046110","sponsor":"Novo Nordisk A/S","briefTitle":"Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin","officialTitle":"A Trial Comparing Efficacy and Safety of NN1250 With Sitagliptin in Insulin Naive Subjects With Type 2 Diabetes (BEGIN™ : EARLY)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01","primaryCompletion":"2010-11","completion":"2010-11","firstPosted":"2010-01-11","resultsPosted":"2015-11-18","lastUpdate":"2017-03-03"},"enrollment":458,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"insulin degludec","otherNames":[]},{"type":"DRUG","name":"sitagliptin","otherNames":[]}],"arms":[{"label":"IDeg OD","type":"EXPERIMENTAL"},{"label":"DPP-IV inhibitor","type":"EXPERIMENTAL"}],"summary":"This trial will be conducted in Africa, Asia, North America and South America. The aim of this clinical trial is to compare NN1250 (insulin degludec) with sitagliptin, as add-on to subject's own current oral antidiabetic (OAD) treatment, in subjects with type 2 diabetes inadequately controlled with 1-2 OADs (metformin, sulphonylurea, glinides or pioglitazone).","primaryOutcome":{"measure":"Change in Glycosylated Haemoglobin (HbA1c)","timeFrame":"Week 0, Week 26","effectByArm":[{"arm":"IDeg OD","deltaMin":-1.56,"sd":1.09},{"arm":"DPP-IV Inhibitor","deltaMin":-1.22,"sd":1.16}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":93,"countries":["United States","Argentina","Canada","India","Mexico","South Africa","Turkey (Türkiye)"]},"refs":{"pmids":["23577643"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":226},"commonTop":["Headache","Diarrhoea","Nasopharyngitis","Nausea"]}}